Sort   by:  
 Page size 
UnknownExtended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Not available
S-EPMC6317338 | biostudies-literature
UnknownFinal Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia.
Not available
S-EPMC10448866 | biostudies-literature
UnknownSARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination.
Not available
S-EPMC9762734 | biostudies-literature
UnknownEfficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
Not available
S-EPMC7787219 | biostudies-literature
UnknownElective surgery cancellations due to the COVID-19 pandemic: global predictive modelling to inform surgical recovery plans.
Not available
S-EPMC7272903 | biostudies-literature
Sort   by:  
 Page size